Patients with androgenetic alopecia have four management options:
The majority of men may decide to do nothing. Most women, however, are severely distressed by hair loss and seek medical advice. The aim of pharmacologic treatment, which is different for men and women, is to reverse or stabilize the miniaturization of hair follicles and stimulate hair regrowth.
Men who opt for conservative management
Many men with mild androgenetic alopecia will decide not to use treatment. For these men, a watch-and-wait policy may be appropriate. Tinted cosmetics, hair lightening, and creative hair styling may help to camouflage the defect. Hairpieces or hair extensions may also cover the scalp.[15]Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005 Feb;52(2):301-11.
http://www.ncbi.nlm.nih.gov/pubmed/15692478?tool=bestpractice.com
[31]Shapiro J. Clinical practice. Hair loss in women. N Engl J Med. 2007 Oct 18;357(16):1620-30.
http://www.ncbi.nlm.nih.gov/pubmed/17942874?tool=bestpractice.com
Men who opt for medical management
Currently, only topical minoxidil (2% and 5%) and oral finasteride are approved for the medical management of male-pattern baldness.[11]European Dermatology Forum. S3 - European Dermatology Forum guideline for the treatment of androgenetic alopecia in women and in men. 2017 [internet publication].
https://www.guidelines.edf.one//uploads/attachments/cl262ylye009ulajnpuci9r2i-androgenetic-alopecia-2017-gl.pdf
[15]Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005 Feb;52(2):301-11.
http://www.ncbi.nlm.nih.gov/pubmed/15692478?tool=bestpractice.com
Both medications can slow down hair loss, and to a lesser extent produce regrowth of lost hair; however, complete reversal of hair loss is never achieved. Oral dutaseride is another option. However, while it is approved for this indication in some countries, male pattern hair loss is an unlicensed use in the US and Europe. Low-dose oral minoxidil has become more popular for hair loss, but is an off-label use. Based on a meta-analysis, dutasteride is more efficacious than finasteride, which is in turn more efficacious than minoxidil (oral and topical).[32]Gupta AK, Venkataraman M, Talukder M, et al. Relative efficacy of minoxidil and the 5-α reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis. JAMA Dermatol. 2022 Mar 1;158(3):266-74.
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35107565
http://www.ncbi.nlm.nih.gov/pubmed/35107565?tool=bestpractice.com
Usually, the most appropriate option is to start with a single treatment and monitor response for at least 6 to 12 months, before a decision is made about efficacy and before a second treatment is tried or a combination of minoxidil and finasteride is used. All therapies may need to be used indefinitely to maintain their effect. If treatment is discontinued, benefit is lost over time, and the hair density will regress to baseline.
Topical minoxidil
Initially introduced as an antihypertensive drug, minoxidil (used topically for this indication) is approved for androgenetic alopecia in men.[11]European Dermatology Forum. S3 - European Dermatology Forum guideline for the treatment of androgenetic alopecia in women and in men. 2017 [internet publication].
https://www.guidelines.edf.one//uploads/attachments/cl262ylye009ulajnpuci9r2i-androgenetic-alopecia-2017-gl.pdf
[33]Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007 Nov;57(5):767-74.
http://www.ncbi.nlm.nih.gov/pubmed/17761356?tool=bestpractice.com
[34]Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017 Jul;77(1):136-41.e5.
http://www.ncbi.nlm.nih.gov/pubmed/28396101?tool=bestpractice.com
It is a potassium-channel opener and potent vasodilator, but its mechanism of action for hair regrowth is unknown. The drug appears to increase the duration of the anagen phase and reverses miniaturization of hair follicles through angiogenic effects.[35]Buhl AE, Waldon, DJ, Conrad SJ, et al. Potassium channel conductance: a mechanism affecting hair growth both in vitro and in vivo. J Invest Dermatol. 1992 Mar;98(3):315-9.
http://www.ncbi.nlm.nih.gov/pubmed/1545141?tool=bestpractice.com
The 5% solution is associated with more robust hair growth compared with the 2% solution in men.[36]Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol. 1999 Nov;41(5 Pt 1):717-21.
http://www.ncbi.nlm.nih.gov/pubmed/10534633?tool=bestpractice.com
[37]Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002 Sep;47(3):377-85.
http://www.ncbi.nlm.nih.gov/pubmed/12196747?tool=bestpractice.com
[38]Tsuboi R, Arano O, Nishikawa T, et al. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men. J Dermatol. 2009 Aug;36(8):437-46.
http://www.ncbi.nlm.nih.gov/pubmed/19691748?tool=bestpractice.com
The 5% foam formulation may cause less irritation than the 5% solution due to the absence of propylene glycol.[39]Kanti V, Hillmann K, Kottner J, et al. Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104-week open-label clinical trial. J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1183-9.
http://www.ncbi.nlm.nih.gov/pubmed/26387973?tool=bestpractice.com
It may also be more cosmetically pleasing to use.
Finasteride
Originally developed for the treatment of benign prostate hyperplasia, finasteride is approved for adult men with androgenetic alopecia.[11]European Dermatology Forum. S3 - European Dermatology Forum guideline for the treatment of androgenetic alopecia in women and in men. 2017 [internet publication].
https://www.guidelines.edf.one//uploads/attachments/cl262ylye009ulajnpuci9r2i-androgenetic-alopecia-2017-gl.pdf
[27]Whiting DA, Olsen EA, Savin R, et al. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol. 2003 Mar-Apr;13(2):150-60.
http://www.ncbi.nlm.nih.gov/pubmed/12695131?tool=bestpractice.com
[34]Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017 Jul;77(1):136-41.e5.
http://www.ncbi.nlm.nih.gov/pubmed/28396101?tool=bestpractice.com
It irreversibly binds to the type II 5-alpha-reductase isoenzyme and inhibits the conversion of testosterone to dihydrotestosterone (DHT). Clinical studies have shown that target area hair counts are significantly increased in men after 12 months of therapy.[11]European Dermatology Forum. S3 - European Dermatology Forum guideline for the treatment of androgenetic alopecia in women and in men. 2017 [internet publication].
https://www.guidelines.edf.one//uploads/attachments/cl262ylye009ulajnpuci9r2i-androgenetic-alopecia-2017-gl.pdf
[40]Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):578-89.
http://www.ncbi.nlm.nih.gov/pubmed/9777765?tool=bestpractice.com
Sexually related adverse effects, such as decreased libido or erectile dysfunction, may occur, but may be reversible after discontinuation of the drug.[27]Whiting DA, Olsen EA, Savin R, et al. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol. 2003 Mar-Apr;13(2):150-60.
http://www.ncbi.nlm.nih.gov/pubmed/12695131?tool=bestpractice.com
[40]Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):578-89.
http://www.ncbi.nlm.nih.gov/pubmed/9777765?tool=bestpractice.com
[41]Lee S, Lee YB, Choe SJ, et al. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. Acta Derm Venereol. 2019 Jan 1;99(1):12-17.
https://www.doi.org/10.2340/00015555-3035
http://www.ncbi.nlm.nih.gov/pubmed/30206635?tool=bestpractice.com
There are reports of so-called "post-finasteride syndrome" consisting of persistent sexual adverse effects along with depression, anxiety, suicidal ideation and cognitive impairment.[42]Nguyen DD, Marchese M, Cone EB, et al. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol. 2021 Jan 1;157(1):35-42.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658800
http://www.ncbi.nlm.nih.gov/pubmed/33175100?tool=bestpractice.com
The true incidence of this and its relationship to finasteride use is unclear.[11]European Dermatology Forum. S3 - European Dermatology Forum guideline for the treatment of androgenetic alopecia in women and in men. 2017 [internet publication].
https://www.guidelines.edf.one//uploads/attachments/cl262ylye009ulajnpuci9r2i-androgenetic-alopecia-2017-gl.pdf
Treatment switch
Combination treatment
Based on a few studies in humans and animals, the combination of topical minoxidil and oral finasteride appears to act synergistically and be superior compared with monotherapy.[11]European Dermatology Forum. S3 - European Dermatology Forum guideline for the treatment of androgenetic alopecia in women and in men. 2017 [internet publication].
https://www.guidelines.edf.one//uploads/attachments/cl262ylye009ulajnpuci9r2i-androgenetic-alopecia-2017-gl.pdf
[15]Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005 Feb;52(2):301-11.
http://www.ncbi.nlm.nih.gov/pubmed/15692478?tool=bestpractice.com
The degree of hair loss-associated distress in the patient should guide the decision regarding beginning minoxidil or finasteride as monotherapy initially, or beginning both simultaneously to maximize early treatment benefits. If monotherapy is chosen, the effects should be monitored for at least 6 to 12 months before a second treatment choice is added in those who show an initial poor response.
Women who opt for conservative management
Some women with mild pattern hair loss may decide not to use treatment. For these women, a watch-and-wait policy may be appropriate. Tinted cosmetics, hair lightening, and creative hair styling may help to camouflage the defect. Hairpieces or hair extensions may also cover the scalp.[15]Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005 Feb;52(2):301-11.
http://www.ncbi.nlm.nih.gov/pubmed/15692478?tool=bestpractice.com
[31]Shapiro J. Clinical practice. Hair loss in women. N Engl J Med. 2007 Oct 18;357(16):1620-30.
http://www.ncbi.nlm.nih.gov/pubmed/17942874?tool=bestpractice.com
Women who opt for medical management
Currently, minoxidil topical 2% solution and 5% foam are the only treatments approved for pattern hair loss in women in the US.[7]Starace M, Orlando G, Alessandrini A, et al. Female androgenetic alopecia: an update on diagnosis and management. Am J Clin Dermatol. 2020 Feb;21(1):69-84.
http://www.ncbi.nlm.nih.gov/pubmed/31677111?tool=bestpractice.com
[11]European Dermatology Forum. S3 - European Dermatology Forum guideline for the treatment of androgenetic alopecia in women and in men. 2017 [internet publication].
https://www.guidelines.edf.one//uploads/attachments/cl262ylye009ulajnpuci9r2i-androgenetic-alopecia-2017-gl.pdf
[15]Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005 Feb;52(2):301-11.
http://www.ncbi.nlm.nih.gov/pubmed/15692478?tool=bestpractice.com
[34]Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017 Jul;77(1):136-41.e5.
http://www.ncbi.nlm.nih.gov/pubmed/28396101?tool=bestpractice.com
Oral finasteride and other antiandrogens are sometimes used off-label. Similarly to in men, treatments slow hair loss, with a lower likelihood of improving hair growth. Minoxidil is contraindicated in pregnancy and lactation. Oral finasteride and antiandrogens are contraindicated in pregnant women due to the risk of feminizing a male fetus.
Topical minoxidil
Minoxidil topical 5% foam has been shown to be noninferior to the 2% solution. The foam tends to be more tolerable than the solution and may be more cosmetically acceptable.[43]Blume-Peytavi U, Hillmann K, Dietz E, et al. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011 Dec;65(6):1126-1134.e2.
http://www.ncbi.nlm.nih.gov/pubmed/21700360?tool=bestpractice.com
Although not approved for women in the US, minoxidil topical 5% solution has also been shown to be significantly more effective than placebo both by target hair counts and subject assessment.[44]Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004 Apr;50(4):541-53.
http://www.ncbi.nlm.nih.gov/pubmed/15034503?tool=bestpractice.com
The 5% minoxidil topical solution appears to be safe in women with the only additional risks of the 5% over the 2% solution being a higher incidence of facial hypertrichosis and scalp irritation.[11]European Dermatology Forum. S3 - European Dermatology Forum guideline for the treatment of androgenetic alopecia in women and in men. 2017 [internet publication].
https://www.guidelines.edf.one//uploads/attachments/cl262ylye009ulajnpuci9r2i-androgenetic-alopecia-2017-gl.pdf
[15]Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005 Feb;52(2):301-11.
http://www.ncbi.nlm.nih.gov/pubmed/15692478?tool=bestpractice.com
However, the 5% foam does not cause as much of an increase in facial hypertrichosis as compared to the 2% solution.[43]Blume-Peytavi U, Hillmann K, Dietz E, et al. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011 Dec;65(6):1126-1134.e2.
http://www.ncbi.nlm.nih.gov/pubmed/21700360?tool=bestpractice.com
Anecdotally, preference for solution versus foam varies greatly based on the individual patient.
Finasteride
Uncontrolled studies suggest a benefit of finasteride in normoandrogenic women after 12 months of treatment.[11]European Dermatology Forum. S3 - European Dermatology Forum guideline for the treatment of androgenetic alopecia in women and in men. 2017 [internet publication].
https://www.guidelines.edf.one//uploads/attachments/cl262ylye009ulajnpuci9r2i-androgenetic-alopecia-2017-gl.pdf
[45]Yeon JH, Jung JY, Choi JW, et al. 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol. 2011 Feb;25(2):211-4.
http://www.ncbi.nlm.nih.gov/pubmed/20569283?tool=bestpractice.com
[46]Oliveira-Soares R, E Silva JM, Correia MP, et al. Finasteride 5 mg/day Treatment of Patterned Hair Loss in Normo-androgenetic Postmenopausal Women. Int J Trichology. 2013 Jan;5(1):22-5.
https://www.doi.org/10.4103/0974-7753.114709
http://www.ncbi.nlm.nih.gov/pubmed/23960392?tool=bestpractice.com
However, a controlled study in postmenopausal women with pattern hair loss showed no difference in finasteride (at a lower dose) as compared to placebo.[11]European Dermatology Forum. S3 - European Dermatology Forum guideline for the treatment of androgenetic alopecia in women and in men. 2017 [internet publication].
https://www.guidelines.edf.one//uploads/attachments/cl262ylye009ulajnpuci9r2i-androgenetic-alopecia-2017-gl.pdf
[47]Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000 Nov;43(5 pt 1):768-76.
http://www.ncbi.nlm.nih.gov/pubmed/11050579?tool=bestpractice.com
Antiandrogen therapy
Antiandrogen therapies such as spironolactone, cyproterone, flutamide, and bicalutamide have been studied in a limited fashion in women with and without hyperandrogenism and female pattern hair loss. The benefit is limited in these studies, but women with concomitant hyperandrogenism (<40% of cases) may benefit more from antiandrogen therapy.[31]Shapiro J. Clinical practice. Hair loss in women. N Engl J Med. 2007 Oct 18;357(16):1620-30.
http://www.ncbi.nlm.nih.gov/pubmed/17942874?tool=bestpractice.com
[48]Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005 Mar;152(3):466-73.
http://www.ncbi.nlm.nih.gov/pubmed/15787815?tool=bestpractice.com
Cyproterone is not available in the US, but is available in Europe and many other countries. All women on anti-androgens should use effective means of contraception while taking these drugs.[11]European Dermatology Forum. S3 - European Dermatology Forum guideline for the treatment of androgenetic alopecia in women and in men. 2017 [internet publication].
https://www.guidelines.edf.one//uploads/attachments/cl262ylye009ulajnpuci9r2i-androgenetic-alopecia-2017-gl.pdf
[15]Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005 Feb;52(2):301-11.
http://www.ncbi.nlm.nih.gov/pubmed/15692478?tool=bestpractice.com
This protects against the risk of pregnancy and feminization of male fetuses. A combined contraceptive pill with a progestin of low androgenic activity such as norgestimate is recommended. Bicalutamide is a selective androgen receptor antagonist with a higher affinity and better safety profile as compared to flutamide.[49]Ismail FF, Meah N, Trindade de Carvalho L, et al. Safety of oral bicalutamide in female pattern hair loss: a retrospective review of 316 patients. J Am Acad Dermatol. 2020 Nov;83(5):1478-9.
http://www.ncbi.nlm.nih.gov/pubmed/32213304?tool=bestpractice.com
[50]Fernandez-Nieto D, Saceda-Corralo D, Jimenez-Cauhe J, et al. Bicalutamide: a potential new oral antiandrogenic drug for female pattern hair loss. J Am Acad Dermatol. 2020 Nov;83(5):e355-6.
http://www.ncbi.nlm.nih.gov/pubmed/32320770?tool=bestpractice.com
Oral contraceptives alone also reduce the production of androgens and increase sex hormone-binding globulin, resulting in a decrease of free testosterone levels.[51]Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs. 2003;63(5):463-92.
http://www.ncbi.nlm.nih.gov/pubmed/12600226?tool=bestpractice.com
Oral contraceptives containing a progestin with antiandrogenic activity (e.g., drospirenone/ethinyl estradiol) are recommended.
Hair transplant surgery for failed medical treatment
Few patients will enjoy robust regrowth of hair with medical therapy. Those who desire restoration of greater density of hair than medications will provide may be appropriate candidates for hair transplantation.[11]European Dermatology Forum. S3 - European Dermatology Forum guideline for the treatment of androgenetic alopecia in women and in men. 2017 [internet publication].
https://www.guidelines.edf.one//uploads/attachments/cl262ylye009ulajnpuci9r2i-androgenetic-alopecia-2017-gl.pdf
[15]Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005 Feb;52(2):301-11.
http://www.ncbi.nlm.nih.gov/pubmed/15692478?tool=bestpractice.com
Ideal male candidates should be over 25 years of age with high-density donor hair and just frontal and mid-frontal hair loss. Ideal female candidates should have high-density donor hair and extensive hair loss or thinning of the frontal scalp.
Modern hair transplant surgery consists solely of follicular unit transplantation using grafts produced from traditional strip harvesting or follicular unit extraction or excision. Older techniques including punch grafts, mini-grafts, micro-grafts, slit grafts, and strip grafts are outmoded and will not produce acceptable results.[52]Sadick NS, White MP. Basic hair transplantation: 2007. Dermatol Ther. 2007 Nov-Dec;20(6):436-47.
http://www.ncbi.nlm.nih.gov/pubmed/18093017?tool=bestpractice.com
Follicular-unit transplantation gives the most natural-appearing results. Possible complications of hair transplants include infection, scarring around the grafts, poor growth of grafts, keloid formation, persistent scalp pain, telogen effluvium, and arteriovenous fistula formation, although all these complications are extremely rare in experienced hands.
Adjunctive use of finasteride and/or topical minoxidil may stabilize underlying hair loss, which will allow the patient to maintain a more natural appearance over time.[11]European Dermatology Forum. S3 - European Dermatology Forum guideline for the treatment of androgenetic alopecia in women and in men. 2017 [internet publication].
https://www.guidelines.edf.one//uploads/attachments/cl262ylye009ulajnpuci9r2i-androgenetic-alopecia-2017-gl.pdf
[15]Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005 Feb;52(2):301-11.
http://www.ncbi.nlm.nih.gov/pubmed/15692478?tool=bestpractice.com